Baloncibart

Monoclonal antibody

Also known as REGN7544

Ungradedevidence

Evidence outlook

Mid- and late-stage studies completed

This drug has completed mid- or late-stage studies. Where a sponsor has not posted registry results, topline data typically arrives via company announcements; see News.

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.

Phase 2 (2)
Postural Orthostatic Tachycardia Syndrome
NCT06593600 · Regeneron Pharmaceuticals
2024-11-13 – 2026-07-08 · Postural Orthostatic Tachycardia Syndrome (POTS)
What this study did
Other / comorbidity
NCT06608901 · Regeneron Pharmaceuticals
2025-05-05 – 2026-04-28 · Sepsis-Induced Hypotension
What this study did
Phase 1 (1)
Other / comorbidity
NCT05970718 · Regeneron Pharmaceuticals
2023-08-07 – 2024-07-22 · Healthy Volunteers
What this study did

Competitive landscape

No competitors sharing a mechanism or indication in the current universe.

Upcoming events

No upcoming readouts on record for this asset.

Regulatory and conference events

(1)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

30 October 2026Topline resultPhase 2 sepsis-induced hypotension study missed primary endpoint